The running themes of treating and preventing HIV will be highlighted early in the plenary session held on Monday morning.

In a recent study published in the journal PLOS Biology, researchers in France investigated the cellular function and antiviral role of human SAMD9L and its paralog SAMD9 (short for sterile alpha ...

Phase 3 trial results demonstrate the superiority of long-acting injectable cabotegravir + rilpivirine over daily oral ...

HIV-1 can be neutralized by antibodies which bind to vulnerable structures on the virus surface. One such vulnerable site is ...

In an important discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human immunodeficiency ...

A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability that could lead to new therapies and bring the world closer to a ...

Scientists have unveiled insights into how HIV-1, the virus responsible for AIDS, skillfully hijacks cellular machinery for its own survival. By dissecting the molecular interplay between the virus ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

Combination antiretroviral therapy (ART) has transformed HIV-1 infection into a chronic condition with near-normal life expectancy. For more than two decades, the standard regimen has been a ...